2019
DOI: 10.1039/c8ra07470d
|View full text |Cite
|
Sign up to set email alerts
|

Improvement of high-glucose and insulin resistance of chromium malate in 3T3-L1 adipocytes by glucose uptake and insulin sensitivity signaling pathways and its mechanism

Abstract: Previous study has revealed that chromium malate could improve insulin resistance and the regulation of fasting blood glucose in type 2 diabetic rats. This study was designed to investigate the effect of chromium malate on hypoglycemic and improve insulin resistance activities in 3T3-L1 adipocytes with insulin resistance and investigate the acting mechanism. The result indicated that chromium malate exhibited direct hypoglycemic activity in vitro. Compared with the model group, chromium malate could significan… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 10 publications
(3 citation statements)
references
References 38 publications
0
3
0
Order By: Relevance
“…Feng et al [ 54 ] explored the effect of chromium malate in ameliorating insulin resistance in the 3T3-L1 adipocyte model. Fully adipocyte-mature 3T3-L1 cells were obtained after 2 days of treatment with insulin (10 mg/mL) and IBMX (0.5 mM), followed by 5 days of treatment with 10% FBS-DMEM.…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…Feng et al [ 54 ] explored the effect of chromium malate in ameliorating insulin resistance in the 3T3-L1 adipocyte model. Fully adipocyte-mature 3T3-L1 cells were obtained after 2 days of treatment with insulin (10 mg/mL) and IBMX (0.5 mM), followed by 5 days of treatment with 10% FBS-DMEM.…”
Section: Resultsmentioning
confidence: 99%
“…This effect is related to the downregulation of the glucose uptake-related pathways (GLUT4, Akt, and p-Akt). In addition, it inhibits insulin-sensitive signaling pathways, including IRS1, PPAR γ , PI3K, and p38-MAPK, at both mRNA and protein levels [ 54 ].…”
Section: Resultsmentioning
confidence: 99%
“…Cr (III); as an insulin dependent glucose transporter antidiabetic; suppresses the effects of harmful serum lipids (Feng et al 2019), on the other hand some immune-modulatory medications elevate blood sugar level and cause dyslipidemia with their consequences and complications (Penfornis and Kury-Paulin 2006). Preventing dyslipidemia would be protective from premature atherosclerosis associating RA (Arias de la Rosa et al 2018).…”
Section: Inflammopharmacologymentioning
confidence: 99%